- Home
- A-Z Publications
- South African Medical Journal
- Previous Issues
- Volume 100, Issue 4, 2010
South African Medical Journal - Volume 100, Issue 4, April 2010
Volumes & issues
-
Volume 108 (2018)
-
Volume 107 (2017)
-
Volume 106 (2016)
-
Supplement 1
-
Volume 105 (2015)
-
Volume 104 (2014)
-
Volume 103 (2013)
-
Volume 102 (2012)
-
Volume 101 (2011)
-
Supplement 1
-
Volume 100 (2010)
-
Volume 99 (2009)
-
Volume 98 (2008)
-
Volume 97 (2007)
-
Volume 96 (2006)
-
Volume 95 (2005)
-
Volume 94 (2004)
-
Volume 93 (2003)
-
Volume 75 (1989)
-
Volume 74 (1988)
-
Volume 73 (1988)
-
Volume 72 (1987)
-
Volume 71 (1987)
-
Volume 70 (1986)
-
Volume 69 (1986)
-
Volume 68 (1985)
-
Volume 67 (1985)
-
Volume 66 (1984)
-
Volume 65 (1984)
-
Volume 64 (1983)
-
Volume 63 (1983)
-
Volume 62 (1982)
-
Volume 61 (1982)
-
Volume 60 (1981)
-
Volume 59 (1981)
-
Volume 58 (1980)
-
Volume 57 (1980)
-
Volume 56 (1979)
-
Volume 55 (1979)
-
Volume 54 (1978)
-
Volume 53 (1978)
-
Volume 52 (1977)
-
Volume 51 (1977)
-
Volume 50 (1976)
-
Volume 49 (1975)
-
Volume 48 (1974)
-
Volume 47 (1973)
-
Volume 46 (1972)
-
Volume 45 (1971)
-
Volume 44 (1970)
-
Volume 8 ([1934, 1970])
-
Volume 43 (1969)
-
Volume 7 ([1933, 1969])
-
Volume 42 (1968)
-
Volume 6 ([1932, 1968])
-
Volume 41 (1967)
-
Volume 5 (1967)
-
Volume 40 (1966)
-
Volume 4 (1966)
-
Volume 39 (1965)
-
Volume 3 ([1965, 1929])
-
Volume 38 (1964)
-
Volume 10 ([1936, 1964])
-
Volume 37 (1963)
-
Volume 36 (1962)
-
Volume 35 (1961)
-
Volume 34 (1960)
-
Volume 33 (1959)
-
Volume 32 (1958)
-
Volume 31 (1957)
-
Volume 30 (1956)
-
Volume 29 (1955)
-
Volume 28 (1954)
-
Volume 27 (1953)
-
Volume 26 (1952)
-
Volume 25 (1951)
-
Volume 24 (1950)
-
Volume 23 (1949)
-
Volume 22 (1948)
-
Volume 21 (1947)
-
Volume 20 ([1922, 1946])
-
Volume 18 ([1920, 1944])
-
Volume 17 ([1919, 1943])
-
Volume 16 (1942)
-
Volume 15 ([1941, 1917])
-
Volume 14 (1940)
-
Volume 13 (1939)
-
Volume 12 (1938)
-
Volume 11 (1937)
-
Volume 10 ([1936, 1964])
-
Volume 9 (1935)
-
Volume 8 ([1934, 1970])
-
Volume 7 ([1933, 1969])
-
Volume 6 ([1932, 1968])
-
Volume 3 ([1965, 1929])
-
Volume 2 (1928)
-
Volume 1 (1927)
-
Volume 20 ([1922, 1946])
-
Volume 19 (1921)
-
Volume 18 ([1920, 1944])
-
Volume 17 ([1919, 1943])
-
Volume 15 ([1941, 1917])
Volume 100, Issue 4, April 2010
-
Total perinatally related losses at Tygerberg Hospital - a comparison between 1986, 1993 and 2006 : original article
Authors: Quonita Talip, Gerhard Theron, Wilhelm Steyn and David HallSource: South African Medical Journal 100, pp 250 –253 (2010)More LessObjective. To determine the leading causes of perinatal deaths and to evaluate any changes, with the inclusion of placental histology.
Method. At perinatal mortality meetings, primary and final causes of death were assigned for the period 1 July 2006 - 30 June 2007. All singleton babies born to women residing in the metropolitan area serviced by Tygerberg Hospital were included in the prospective descriptive study.
Results. The total number of singleton births was 10 396. The total of perinatally related losses (TPRL) rate was 26.2 per 1 000 births. The leading primary obstetric causes of death were: infections (47 - 17.3%), spontaneous preterm labour (PTL) (41 - 15.1%), antepartum haemorrhage (APH) (40 - 14.7%), intra-uterine growth restriction (IUGR) (40 - 14.7%), fetal abnormality (31 - 11.4%), hypertensive disorders (25 - 9.2%), unexplained intra-uterine deaths (IUD) (20 - 7.4%), intrapartum hypoxia (12 - 4.4%) and maternal disease (9 - 3.3%). A total of 162 placentas were sent for histology; 58 reports changed the primary cause of death.
Conclusion. The TPRL rate for singleton pregnancies was 26.2 per 1 000 births for the study period. The TPRL rates in 1986 and 1993 were 36.7 and 30.5 per 1 000 deliveries. Infection is now the leading primary cause of death, followed by spontaneous PTL, APH and IUGR. During the previous two study periods, APH was the leading primary cause of death, followed by spontaneous PTL. Unexplained IUDs ranked third in 1986, fourth in 1993 and seventh in this study because of the availability of placental histology. Placental histology reports changed 21.3% of the primary causes of death.
-
Guideline on the management of psoriasis in South Africa : guideline
Authors: N. Raboobee, J. Aboobaker, H.F. Jordaan, W. Sinclair, J.M. Smith, G. Todd, R. Weiss and D. WhitakerSource: South African Medical Journal 100, pp 257 –282 (2010)More LessBackground. Psoriasis vulgaris is a chronic, relapsing, immune-mediated, potentially devastating disease, influenced by genetic and environmental factors, that can cause substantial morbidity and psychological stress and have a profound negative impact on patient quality of life.
Objective. These guidelines for the management of psoriasis have been developed in an attempt to improve the outcomes of treatment of this condition in South Africa. Psoriasis has a major impact on the quality of life of sufferers, and it is expected that these guidelines, if implemented, will play a role in achieving improved outcome.
Scope. These guidelines were developed to address the diagnosis and treatment of psoriasis, of differing degrees of severity and in patients of all ages, by all health care professionals involved with its management.
Recommendations. All health care workers involved in the management of psoriasis should take note of these guidelines and try to implement them in clinical practice as far as possible. All treatment methods and procedures not substantiated by evidence from the literature should be discontinued and avoided to decrease the financial burden of psoriasis treatment.
Validation. These guidelines were developed through general consensus by a group of 8 South African dermatologists (the 'Working Group') sanctioned by the Dermatological Society of South Africa (DSSA), by adaptation for the South African situation of the current guidelines used in the USA, the UK, Germany, Canada and Finland. Draft documents were made available for comment to the dermatological community as a whole via the official website of the DSSA, and the guidelines were presented and discussed at the annual congress of the DSSA in 2008. All input from these sources, where appropriate, were then incorporated into these guidelines.
Guidelines sponsor. Schering-Plough initiated the project and sponsored the meetings of the working group and all costs generated by these meetings.
Plans for guideline revision. The field of biologicals and cytokine modulators is in a rapid phase of development, and revision of the scope and content of these guidelines will be ongoing as longer-term data emerge.